Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection.


Journal

Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674

Informations de publication

Date de publication:
08 2022
Historique:
received: 28 04 2022
revised: 24 06 2022
accepted: 29 06 2022
pubmed: 15 7 2022
medline: 22 7 2022
entrez: 14 7 2022
Statut: ppublish

Résumé

A prototype strain of Coxsackievirus A21 (CVA21) is under clinical evaluation as an oncolytic virus immunotherapy. To improve scalability of the manufacturing process, an affinity chromatography purification method was developed using immobilized glutathione resin that captured infectious CVA21 virions from cell culture harvests with high recovery and impurity clearance. Unexpectedly, the binding of empty CVA21 procapsids depended on production cell culture conditions during infection including temperature, presence of serum in the media, and production cell line. At 37 °C and 2% serum during infection, procapsids flowed-through while infectious virions bound and were recovered at >95% yield in the chromatography elution. However, at sub-physiological temperature or after removal of serum at infection, both procapsids and mature virions bound and co-eluted from the immobilized glutathione ligand. This work may improve the understanding of CVA21 capsid assembly and presents an efficient purification method that may be applied to picornaviruses that interact with intracellular GSH.

Identifiants

pubmed: 35834888
pii: S0042-6822(22)00105-2
doi: 10.1016/j.virol.2022.06.013
pii:
doi:

Substances chimiques

Intercellular Adhesion Molecule-1 126547-89-5
Glutathione GAN16C9B8O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-175

Informations de copyright

Copyright © 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc.,. Published by Elsevier Inc. All rights reserved.

Auteurs

Andrew R Swartz (AR)

Process Research and Development, Merck & Co, Inc, Kenilworth, NJ, USA. Electronic address: andrew.swartz@merck.com.

Yvonne Shieh (Y)

Process Research and Development, Merck & Co, Inc, Kenilworth, NJ, USA.

Amanda Gulasarian (A)

Process Research and Development, Merck & Co, Inc, Kenilworth, NJ, USA.

Jessica W Olson (JW)

Process Research and Development, Merck & Co, Inc, Kenilworth, NJ, USA.

Richard R Rustandi (RR)

Analytical Research and Development, Merck & Co, Inc, Kenilworth, NJ, USA.

Articles similaires

Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae

High-throughput Bronchus-on-a-Chip system for modeling the human bronchus.

Akina Mori, Marjolein Vermeer, Lenie J van den Broek et al.
1.00
Humans Bronchi Lab-On-A-Chip Devices Epithelial Cells Goblet Cells
Vinca Alkaloids Animals Carcinoma, Hepatocellular Rats Liver Neoplasms
Osteosarcoma Animals Glutathione Oxidation-Reduction Mice

Classifications MeSH